Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Division of Hematology, Azienda Ospedaliera Policlinico e Vittorio Emanuele di Catania, Catania, Italy.
Sci Rep. 2020 Feb 6;10(1):1983. doi: 10.1038/s41598-020-58859-x.
To understand neutrophil impairment in the progression from MGUS through active MM, we investigated the function of mature, high-density neutrophils (HDNs), isolated from peripheral blood. In 7 MM, 3 MGUS and 3 healthy subjects by gene expression profile, we identified a total of 551 upregulated and 343 downregulated genes in MM-HDN, involved in chemokine signaling pathway and FC-gamma receptor mediated phagocytosis conveying in the activation of STAT proteins. In a series of 60 newly diagnosed MM and 30 MGUS patients, by flow-cytometry we found that HDN from MM, and to a lesser extend MGUS, had an up-regulation of the inducible FcγRI (also known as CD64) and a down-regulation of the constitutive FcγRIIIa (also known as CD16) together with a reduced phagocytic activity and oxidative burst, associated to increased immune-suppression that could be reverted by arginase inhibitors in co-culture with lymphocytes. In 43 consecutive newly-diagnosed MM patients, who received first-line treatment based on bortezomib, thalidomide and dexamethasone, high CD64 could identify at diagnosis patients with inferior median overall survival (39.5 versus 86.7 months, p = 0.04). Thus, HDNs are significantly different among healthy, MGUS and MM subjects. In both MGUS and MM neutrophils may play a role in supporting both the increased susceptibility to infection and the immunological dysfunction that leads to tumor progression.
为了了解从 MGUS 发展到活动 MM 过程中中性粒细胞的损伤,我们研究了从外周血中分离出来的成熟、高密度中性粒细胞(HDN)的功能。通过基因表达谱,在 7 例 MM、3 例 MGUS 和 3 例健康对照者中,我们共鉴定出 MM-HDN 中 551 个上调和 343 个下调基因,这些基因涉及趋化因子信号通路和 FC-γ 受体介导的吞噬作用,传递 STAT 蛋白的激活。在一系列 60 例新诊断的 MM 和 30 例 MGUS 患者中,我们通过流式细胞术发现 MM 的 HDN,在一定程度上也包括 MGUS 的 HDN,其诱导型 FcγRI(也称为 CD64)上调,而组成型 FcγRIIIa(也称为 CD16)下调,同时吞噬活性和氧化爆发降低,与免疫抑制增加有关,这种免疫抑制在与淋巴细胞共培养时可被精氨酸酶抑制剂逆转。在 43 例连续新诊断的 MM 患者中,这些患者接受了以硼替佐米、沙利度胺和地塞米松为基础的一线治疗,高 CD64 可在诊断时识别出总生存中位数较差的患者(39.5 个月与 86.7 个月,p=0.04)。因此,健康对照者、MGUS 和 MM 患者之间的 HDN 存在显著差异。在 MGUS 和 MM 中,中性粒细胞可能在支持感染易感性增加和导致肿瘤进展的免疫功能障碍方面发挥作用。